Estimates Revisions TScan Therapeutics, Inc.

Stocks

Market Closed - Nasdaq Other stock markets 00:00:00 01/08/2026 +04			5-day change	1st Jan Change
0.7430 ^USD	-1.68%		-6.42%	-25.70%

07-30	Tscan Therapeutics Doses First Patient in Phase 3 ALLOHA-2 Trial Evaluating TSC-101 in Patients with Heme Malignancies	CI
06-22	TScan Therapeutics Presents Initial Data from Cohort C of Ongoing ALLOHA Phase 1 Study Evaluating TSC-101 in Patients with Heme Malignancies Undergoing Allogeneic Hematopoietic Cell Transplantation	CI

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	1m. Revenue rev.	1y. Revenue rev.	1y. EPS revision
	TSCAN THERAPEUTICS, INC.
	WUXI APPTEC CO., LTD.
	ARGENX SE
	BIONTECH SE
	INSMED INCORPORATED
	WUXI BIOLOGICS (CAYMAN) INC.
	GENMAB A/S
	SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.
	EXELIXIS, INC.
	PHARMAESSENTIA CORPORATION
	Average
	Weighted average by Cap.